NCT07828327Not yet recruiting
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
Effectiveness and Safety of Depemokimab in Allergic Bronchopulmonary Aspergillosis (ABPA) With Severe Eosinophilic Asthma(SEA): a Prospective Study of Real-world Experience
Source: ClinicalTrials.gov · Last updated 24 Sept 2026
Brief summary (registry, in English)
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 14 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Qianfoshan Hospital
- Diseases
- Asthma
- NCT number
- NCT07828327
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 1 Nov 2026 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.
Other illness
- History of allergy or hypersensitivity reaction to Depemokimab or any of its components.
Other
- Currently pregnant, breastfeeding, or lactating women.
Who the study is looking for
- Female and Male patients aged 18-75 years
- Diagnosis of Allergic Bronchopulmonary Aspergillosis (according to the ISHAM Working Group Diagnostic Criteria)
- Severe asthma requiring treatment with high dose ICS plus a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), or maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.